Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

Kaposi sarcoma-associated herpesvirus testing is not routinely performed on donors or reci ...

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all ...

The University of Iowa Health Care Holden Comprehensive Cancer Center has started treating its second patient — the second in the state — with a cellular therapy to fight synovial sarcoma, a rare and ...

Rates infection related cancer have increased among solid organ transplant recipients, CDC reports a five-fold rise in Kaposi sarcoma virus transmission.

A diagnosis of Kaposi sarcoma is a significant life event, but it is a manageable condition. Because KS is so closely linked to immune function, your treatment will likely involve a collaborative ...

Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults. While it can be cured if completely removed by surgery, recurrence or metastasis, the ...

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

PARIS, FRANCE, 09 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

Purpose Sarcomas are cancers of connective tissue and account for approximately 10–15% of all cancer cases in children aged ≤16 years. Treatment often involves chemotherapy, surgery and radiotherapy.